# AxiomBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axiombio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.axi.om
- Total disclosed funding: $7M
- Latest round: Seed (Jun 1, 2023)
- Investors on record: 1

## About

Axiom is a biotechnology firm focused on leveraging advanced AI models for accurate drug toxicity predictions, enhancing the drug development process for pharmaceutical companies and research institutions.Axiom, founded in 2024 in San Francisco, US, specializes in predictive models for drug toxicity. The company successfully raised USD 8.000 mn in funding on June 1, 2024, from Amplify Partners, Dimension Management, and Zetta Venture Partners. The founder has a history in biotechnology, contributing to the establishment of AI-driven solutions that enhance research efficiency.Axiom specializes in providing advanced AI-driven models that predict drug toxicity with greater accuracy and affordability compared to traditional laboratory and animal testing methods. The core offering includes tools that leverage the world's largest dataset of primary human liver biology to forecast clinical outcomes related to liver injury, among other applications. These models enable pharmaceutical scientists to identify and mitigate toxicity risks early in the drug development process, effectively addressing a significant cause of clinical trial failures. Axiom's customer base consists of major pharmaceutical companies and research institutions globally, with a particular focus on markets in North America and Europe. The company aims to revolutionize the drug development landscape by phasing out outdated experimental methods and offering reliable alternatives that enhance research efficiency.Axiom's revenue model is primarily structured around partnerships with pharmaceutical companies, where clients engage in subscription-based agreements to access its AI modeling services. These transactions typically involve a fee-for-service arrangement, where clients pay for the usage of Axiom's predictive tools, potentially encompassing various offerings, including liver toxicity assessments. Pricing plans for these services range from USD 5,000 to USD 15,000, depending on the specific needs of the client and the complexity of the analysis required. By providing robust predictions that streamline the drug development process, Axiom supports its partners in reducing costs associated with late-stage failures, thereby enhancing their overall R&D productivity. The company’s innovative approach is poised to generate significant interest and financial engagement within the pharmaceutical sector.In 2024, Axiom raised USD 8.000 mn in venture funding to validate its artificial intelligence-based liver toxicity model and expand its platform to other organ systems. The company plans to support pilot studies with pharmaceutical and biotechnology partners. Axiom is targeting expansion into European markets by the end of 2025, focusing on collaboration with additional pharmaceutical companies to enhance its service offerings.

## Funding rounds

- Seed, Jun 1, 2023, $7M — Amplify Partners

## Investors

- Amplify Partners (https://capitalatlas.ai/funds/amplify-partners) — Seed